Alopecia areata universalis elicited during treatment with adalimumab

Pelivani, Nedzmidin; Hassan, Akmal S; Braathen, Lasse R; Hunger, Robert E; Yawalkar, Nikhil (2008). Alopecia areata universalis elicited during treatment with adalimumab. Dermatology, 216(4), pp. 320-3. Basel: Karger 10.1159/000113945

Full text not available from this repository. (Request a copy)

Adalimumab is a fully humanized recombinant anti-tumour-necrosis-factor (TNF-alpha) monoclonal antibody which has been approved for rheumatoid arthritis, active ankylosing spondylitis, psoriatic arthritis and Crohn's disease. We report a case of alopecia areata (AA) universalis occurring 6 months after administration of adalimumab monotherapy in a patient with a long-standing history of psoriatic arthritis and psoriasis. The diagnosis was confirmed by a scalp biopsy which showed a peribulbar infiltrate of both CD4+ and CD8+ T cells, CD1a+ dendritic cells as well as CD68+ and CD163+ macrophages. In addition, immunofluorescence staining for TNF-alpha was found in the mononuclear cell infiltrate. This case suggests a complex role of TNF-alpha in the induction of AA.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Hunger, Robert and Yawalkar, Nikhil

ISSN:

1018-8665

ISBN:

18230980

Publisher:

Karger

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:04

Last Modified:

04 May 2014 23:19

Publisher DOI:

10.1159/000113945

PubMed ID:

18230980

Web of Science ID:

000253912000007

URI:

https://boris.unibe.ch/id/eprint/27678 (FactScience: 109911)

Actions (login required)

Edit item Edit item
Provide Feedback